ReutersPatients Continuing On Sanofi’s Lantus(R) Had Lower Blood Sugar Levels Than …Wall Street JournalBRIDGEWATER, N.J., June 14, 2014 /PRNewswire/ — Sanofi US announced today results from a real world outcome study of type 2 diabetes (T2D) patients that show switching from Lantus(R) (insulin glargine [rDNA origin] injection) to insulin detemir …Sanofi’s Toujeo Drug Shows Promise as Lantus SuccessorBusinessweekNew rivals to top diabetes drug Lantus show promise in studiesReutersSanofi Reports Positive Phase 3 Results for Toujeo(R)MarketWatchWashington Postall 23 news articles …Read Full Story
Patients Continuing On Sanofi's Lantus(R) Had Lower Blood Sugar Levels Than ... - Wall Street Journal
Real Estate of Cebu
